MaxCyte, Inc.

NASDAQ:MXCT

Medical - Devices

Healthcare
$1.25 +3.98%

+$0.05 today

Market cap
$129.06M
Beta
1.67
P/E (TTM)
-3.2
EPS (TTM)
-$0.37
52W Low $0.64High $2.37

Volume 0.97M

Average 0.95M

MXCT Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

MaxCyte, Inc.NASDAQ: MXCT

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to -64.1%

Operating margin was -64.1% in Q1 FY2026, up 54.2 pp from a year earlier. On a trailing-twelve-month basis it was -119.7%, up 16.2 pp year over year. Over 3 fiscal years it narrowed by 75.3 pp.

Context

  • Operating margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 3 analysts of -76.8% for the fiscal year ending Dec 2026, up from -137.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-64.1%+41.0 pp QoQ
Last fiscal yearDec 2025
-137.1%-4.6 pp YoY
LTMMar 2026
-119.7%+16.2 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+54.2 pp+24.0 pp-30.2 pp
1 year-4.6 pp+60.4 pp+64.9 pp
3 years-75.3 pp+101.2 pp+176.5 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-137.1%
Year-over-year change
-4.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How MXCT compares with its peers on the latest reported figures

  • MXCT's LTM Mar 2026 operating margin of -119.7% is the 5th highest of the 11 companies compared; the peer median is -261.2%.
  • Its year-over-year change of +16.2 pp is the 5th highest of 11, against a peer median of -1.0 pp.
  • Over three fiscal years its change of -75.3 pp compares with a peer median of +74.3 pp.
MXCT Competitors Peer median
Operating Margin for MXCT and competitors
Company Period LTM level YoY 3-year change
OWLTOwlet, Inc.LTM Mar 2026-10.3% +9.9 pp+114.5 pp
LNSRLENSAR, Inc.LTM Mar 2026-28.7% -11.8 pp+15.0 pp
PREPrenetics Global LimitedLTM Mar 2026-33.7% +85.8 pp+460.3 pp
TLSITriSalus Life Sciences, Inc.LTM Mar 2026-62.4% +36.6 pp+234.2 pp
MXCTMaxCyte, Inc.LTM Mar 2026-119.7% +16.2 pp-75.3 pp
PROFProfound Medical Corp.LTM Mar 2026-203.2% +434.5 pp+224.6 pp
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-319.2% -190.5 pp-92.2 pp
NNOXNano-X Imaging Ltd.LTM Dec 2025-466.2% +36.4 pp+812.8 pp
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026-1258.6% -398.8 pp+34.1 pp
AVRAnteris Technologies Global Corp.LTM Mar 2026-5192.9% -1839.0 pp-3936.1 pp
CATXPerspective Therapeutics, Inc.LTM Mar 2026-19419.6% -12641.0 pp-12632.9 pp
Peer median (excluding MXCT) -261.2%-1.0 pp+74.3 pp

Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.89M44.26M41.29M38.63M33.03M
Cost of Revenue3.65M5.1M4.74M7.1M6.22M
Gross Profit30.25M39.16M36.55M31.53M26.8M
Gross Margin89.2%88.5%88.5%81.6%81.2%
Research & Development15.41M19.51M23.82M22.23M20.82M
Selling, General & Admin31.68M44.48M57.04M56.35M47.04M
Operating Expenses48.44M66.52M84.85M82.72M72.09M
Depreciation & Amortization1.42M2.7M4.17M4.79M5.14M
EBITDA(16.61M)(20.75M)(33.75M)(36.27M)(39.49M)
EBITDA Margin-49.0%-46.9%-81.7%-93.9%-119.6%
Operating Income(18.19M)(27.36M)(48.3M)(51.2M)(45.29M)
Operating Margin-53.7%-61.8%-117.0%-132.5%-137.1%
Interest Income150.8K3.92M10.38M10.14M7.27M
Interest Expense1.04M126.9K000
Other Income / Expenses(893.6K)3.79M10.38M10.14M655K
Income Before Tax(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Pre-Tax Margin-56.3%-53.3%-91.8%-106.3%-135.1%
Income Tax Expense00000
Net Income(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Net Margin-56.3%-53.3%-91.8%-106.3%-135.1%
EPS (Basic)(0.22)(0.19)(0.37)(0.39)(0.42)
EPS (Diluted)(0.22)(0.19)(0.37)(0.39)(0.42)
Weighted Avg Shares90.62M101.7M103.27M104.85M106.43M
Weighted Avg Shares (Diluted)90.62M101.7M103.27M104.85M106.43M

MaxCyte, Inc.

NASDAQ:MXCT

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.